Totackle this problem, we developed AMD3100-targeted Bortezomib Liposomes(ATBL) designed for the targeted delivery of bortezomib to MM cells.Uptake of ATBL into MM cells was dependent on CXCR4 and was enhancedcompared to nontargeted liposomes, both in vitro and in vivo. The gene discussed is CXCR4; the disease is Miyoshi myopathy.